SCHEMBL13819477

SCHEMBL13819477

Cc1ccc(C(=O)Cl)c(OCc2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.54
MRGPRX4 Q96LA9 4/20 0.53
MAPT P10636 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PTGER1 P34995 3/20 0.50
PTGER4 P35408 2/20 0.50
PTGER3 P43115 2/20 0.50
PTGER2 P43116 2/20 0.50
MAOB P27338 1/20 0.50
AKR1C3 P42330 2/20 0.48
LRRK2 Q5S007 2/20 0.48
FFAR4 Q5NUL3 1/20 0.47
GLRA1 P23415 1/20 0.47
MAPK1 P28482 1/20 0.46
FOLH1 Q04609 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21327456 0.88 LRRK2 (0.57) MCL1MRGPRX4MAPTTDP1L3MBTL1
SCHEMBL8168015 0.88 MCL1 (0.64) MCL1MRGPRX4MAPTTDP1L3MBTL1
SCHEMBL6450060 0.87 MAPT (0.63) MCL1MRGPRX4MAPTTDP1L3MBTL1
SCHEMBL4939266 0.85 MAOB (0.60) MCL1CYP2C19SMN1; SMN2MAOB
SCHEMBL5228333 0.84 HDAC8 (0.57) MCL1MRGPRX4MAPTCYP2C9CYP2C19
SCHEMBL31375951 0.84 PTGER1 (0.58) MCL1MRGPRX4CYP2C9SMN1; SMN2PTGER1
SCHEMBL27486908 0.83 AKR1C3 (0.49) MCL1MRGPRX4MAPTTDP1L3MBTL1
SCHEMBL21327204 0.82 MCL1 (0.54) MCL1MRGPRX4MAPTTDP1L3MBTL1
SCHEMBL19361431 0.82 PTGES (0.52) MCL1PTGER1MAOBLRRK2FOLH1
SCHEMBL5296788 0.82 KMT2A (0.58) MAPTL3MBTL1SMN1; SMN2PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309578-B2 Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-11-13 US disclosed
US-20110294790-A1 BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294790-A1 BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS HSP90AB1, HSP90AA1, HSP90AB2P MCL1 194/4885MRGPRX4 3064/4885MAPT 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.